These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21352069)

  • 1. Emerging drugs for Waldenström's macroglobulinemia.
    Kastritis E; Terpos E; Dimopoulos MA
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):45-57. PubMed ID: 21352069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Waldenström's macroglobulinemia].
    Poulain S; Wemeau M; Balkaran S; Hivert B; Hautecoeur A; Rossignol J; Fernandez J; Daudignon A; Roumier C; Soenen V; Lepelley P; Lai JL; Morel P; Leleu X
    Rev Med Interne; 2010 May; 31(5):385-94. PubMed ID: 20363537
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
    Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
    Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel treatment regimens for Waldenström's macroglobulinemia.
    García-Sanz R; Ocio EM
    Expert Rev Hematol; 2010 Jun; 3(3):339-50. PubMed ID: 21082984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel agents in the treatment of Waldenström's macroglobulinemia.
    Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
    Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current options to manage Waldenström's macroglobulinemia.
    Benevolo G; Nicolosi M; Santambrogio E; Vitolo U
    Expert Rev Hematol; 2017 Jul; 10(7):637-647. PubMed ID: 28592170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fludarabine in Waldenstrom's macroglobulinemia.
    Souchet-Compain L; Nguyen S; Choquet S; Leblond V
    Expert Rev Hematol; 2013 Jun; 6(3):229-37. PubMed ID: 23782076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
    Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
    Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current and future therapeutic approach for Waldenström's macroglobulinemia.
    Souchet-Cömpain L; Choquet S; Leblond V; Nguyen S
    Immunotherapy; 2014; 6(3):333-48. PubMed ID: 24762077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab-based treatments in Waldenström's macroglobulinemia.
    Dimopoulos MA; Kastritis E; Roussou M; Eleutherakis-Papaiakovou E; Migkou M; Gavriatopoulou M; Tassidou A; Terpos E
    Clin Lymphoma Myeloma; 2009 Mar; 9(1):59-61. PubMed ID: 19362975
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Managing complications secondary to Waldenström's macroglobulinemia.
    Pessach I; Dimopoulos MA; Kastritis E
    Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
    [No Abstract]   [Full Text] [Related]  

  • 12. Waldenström's macroglobulinemia: a clinical perspective in the era of novel therapeutics.
    Dimopoulos MA; Kastritis E; Ghobrial IM
    Ann Oncol; 2016 Feb; 27(2):233-40. PubMed ID: 26598544
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia.
    Dimopoulos MA; Gertz MA; Kastritis E; Garcia-Sanz R; Kimby EK; Leblond V; Fermand JP; Merlini G; Morel P; Morra E; Ocio EM; Owen R; Ghobrial IM; Seymour J; Kyle RA; Treon SP
    J Clin Oncol; 2009 Jan; 27(1):120-6. PubMed ID: 19047284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
    Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
    Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fludarabine in Waldenstrom's macroglobulinemia.
    Leblond V; Choquet S
    Semin Oncol; 2003 Apr; 30(2):239-42. PubMed ID: 12720144
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted therapies in Waldenström macroglobulinemia.
    Burwick N; Roccaro AM; Leleu X; Ghobrial IM
    Curr Opin Investig Drugs; 2008 Jun; 9(6):631-7. PubMed ID: 18516762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A safety profile of medications used to treat Waldenström's macroglobulinemia.
    García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
    Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Waldenström's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center.
    Merchionne F; Procaccio P; Dammacco F
    Crit Rev Oncol Hematol; 2011 Oct; 80(1):87-99. PubMed ID: 21036057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proteasome inhibitor therapy for Waldenström's macroglobulinemia.
    Dimopoulos MA; Terpos E; Kastritis E
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):235-7. PubMed ID: 23562304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenstrom's macroglobulinemia.
    Treon SP; Agus TB; Link B; Rodrigues G; Molina A; Lacy MQ; Fisher DC; Emmanouilides C; Richards AI; Clark B; Lucas MS; Schlossman R; Schenkein D; Lin B; Kimby E; Anderson KC; Byrd JC
    J Immunother; 2001; 24(3):272-9. PubMed ID: 11394506
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.